The Role of Enterolysis and Tamoxifen in Encapsulating Peritoneal Sclerosis: A Successful Case

Encapsulating peritoneal sclerosis (EPS) is a rare complication of peritoneal dialysis which mortality can reach 50%. The usual treatment involves suspension of the technique, medical treatment, and surgical enterolysis. We report the case of a 36-year-old female who undergone continuous ambulatory peritoneal dialysis without complications for 10 years. She presented at the emergency department with abdominal pain and a diagnosis of peritonitis was assumed. The patient developed a systemic inflammatory response, and her abdominal computer tomography (CT) scan showed multiple parietal calcifications. After multiple broad-spectrum antibiotics, an undetermined febrile syndrome persisted, and parenteral nutrition was started. An EPS diagnosis was established and treatment with tamoxifen was proposed. Exploratory laparoscopy was decided, and the intraoperative findings were consistent with EPS. The patient was submitted to extensive enterolysis. A clinical improvement led to a discharge after 60 days of hospitalization. After more than 30 months with tamoxifen, she remains on hemodialysis and doing well. There are no randomized controlled trials to guide EPS management and the following procedures are more difficult to decide, who makes these reports important to the reflection. We describe a case of successful treatment of EPS, with a very severe presentation. The management with enterolysis and tamoxifen contributed decisively to this outcome.

[1]  V. Liakopoulos,et al.  Encapsulating Peritoneal Sclerosis: Pathophysiology and Current Treatment Options , 2019, International journal of molecular sciences.

[2]  A. Gök,et al.  Surgical treatment of post-transplant encapsulating peritoneal sclerosis: A single-center experience. , 2019, Ulusal Travma Ve Acil Cerrahi Dergisi-turkish Journal of Trauma & Emergency Surgery.

[3]  K. Dohi,et al.  Surgical Treatment for Encapsulating Peritoneal Sclerosis: 24 Years' Experience , 2019, Peritoneal Dialysis International.

[4]  K. Brayman,et al.  Surgical Management of Encapsulating Peritoneal Sclerosis: A Case Report in Kidney Transplant Patient , 2018, Case reports in surgery.

[5]  D. Ponce,et al.  A combination of corticosteroid, sirolimus, and intradialytic parenteral nutrition in encapsulating peritoneal sclerosis: Case report and literature review , 2017, Hemodialysis international. International Symposium on Home Hemodialysis.

[6]  David W. Johnson,et al.  Length of Time on Peritoneal Dialysis and Encapsulating Peritoneal Sclerosis — Position Paper for ISPD: 2017 Update , 2017, Peritoneal Dialysis International.

[7]  H. Harigae,et al.  Chronic lupus peritonitis is characterized by the ascites with a large content of interleukin-6. , 2015, The Tohoku journal of experimental medicine.

[8]  R. Selgas,et al.  Can EPS Development Be Avoided with Early Interventions? The Potential Role of Tamoxifen—A Single-Center Study , 2014, Peritoneal Dialysis International.

[9]  R. Selgas,et al.  Tamoxifen Ameliorates Peritoneal Membrane Damage by Blocking Mesothelial to Mesenchymal Transition in Peritoneal Dialysis , 2013, PloS one.

[10]  G. Koçak,et al.  Additive Effectiveness of Everolimus Plus Tamoxifen Therapy in Treatment of Encapsulating Peritoneal Sclerosis , 2012, Renal failure.

[11]  K. Cransberg,et al.  Post-transplantation encapsulating peritoneal sclerosis in a young child. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[12]  Hester F. Lingsma,et al.  Posttransplantation Encapsulating Peritoneal Sclerosis Contributes Significantly to Mortality after Kidney Transplantation , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[13]  Hester F. Lingsma,et al.  Tamoxifen is associated with lower mortality of encapsulating peritoneal sclerosis: results of the Dutch Multicentre EPS Study. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[14]  David W. Johnson,et al.  Encapsulating peritoneal sclerosis: incidence, predictors, and outcomes. , 2010, Kidney international.

[15]  S. Okuno,et al.  THE ROLE OF PERITONEAL LAVAGE AND THE PROGNOSTIC SIGNIFICANCE OF MESOTHELIAL CELL AREA IN PREVENTING ENCAPSULATING PERITONEAL SCLEROSIS , 2010, Peritoneal Dialysis International.

[16]  A. Davenport,et al.  The Pan-Thames EPS study: treatment and outcomes of encapsulating peritoneal sclerosis. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[17]  K. Simpson,et al.  Encapsulating peritoneal sclerosis in the new millennium: a national cohort study. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[18]  M. Pepels,et al.  Sclerosing peritonitis: an unusual cause of ascites in a patient with systemic lupus erythematosus. , 2006, The Netherlands journal of medicine.

[19]  Y. Kawaguchi,et al.  Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[20]  T. Kawai,et al.  Preservation of peritoneal catheter for prevention of encapsulating peritoneal sclerosis. , 2002, Advances in peritoneal dialysis. Conference on Peritoneal Dialysis.

[21]  C. Pollock Diagnosis and Management of Encapsulating Peritoneal Sclerosis , 2001, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[22]  S. Kuriyama,et al.  Corticosteroid therapy in encapsulating peritoneal sclerosis. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[23]  N. Di Paolo,et al.  Peritoneal Sclerosis: One or Two Nosological Entities? , 2000, Seminars in dialysis.

[24]  S. Mujais,et al.  Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. , 2000, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[25]  S. Korbet,et al.  Sclerosing Peritonitis and Systemic Lupus Erythematosus: A Report of Two Cases , 1999, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[26]  Y. Kawaguchi,et al.  Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: a report of the Japanese Sclerosing Encapsulating Peritonitis Study Group. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[27]  W. Geis,et al.  Sclerotic thickening of the peritoneal membrane in maintenance peritoneal dialysis patients. , 1980, Archives of internal medicine.